Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNLI NASDAQ:TLX NASDAQ:VKTX NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNLIDenali Therapeutics$21.66+3.0%$19.80$12.58▼$23.77$3.34B1.031.80 million shs2.18 million shsTLXTelix Pharmaceuticals$9.56+1.2%$10.07$6.28▼$17.30$3.21B-0.11154,081 shs386,781 shsVKTXViking Therapeutics$28.75+0.5%$31.90$22.96▼$43.15$3.32B0.691.96 million shs1.18 million shsXNCRXencor$12.33+2.0%$12.12$6.92▼$18.69$896.37M0.92664,772 shs590,536 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNLIDenali Therapeutics+1.99%+4.37%+8.02%+2.19%+38.38%TLXTelix Pharmaceuticals+0.11%-0.94%-9.05%+20.38%-44.54%VKTXViking Therapeutics+3.10%-3.93%-8.65%-19.70%-1.17%XNCRXencor+2.20%+0.67%-2.81%+0.75%+27.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNLIDenali Therapeutics$21.66+3.0%$19.80$12.58▼$23.77$3.34B1.031.80 million shs2.18 million shsTLXTelix Pharmaceuticals$9.56+1.2%$10.07$6.28▼$17.30$3.21B-0.11154,081 shs386,781 shsVKTXViking Therapeutics$28.75+0.5%$31.90$22.96▼$43.15$3.32B0.691.96 million shs1.18 million shsXNCRXencor$12.33+2.0%$12.12$6.92▼$18.69$896.37M0.92664,772 shs590,536 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNLIDenali Therapeutics+1.99%+4.37%+8.02%+2.19%+38.38%TLXTelix Pharmaceuticals+0.11%-0.94%-9.05%+20.38%-44.54%VKTXViking Therapeutics+3.10%-3.93%-8.65%-19.70%-1.17%XNCRXencor+2.20%+0.67%-2.81%+0.75%+27.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNLIDenali Therapeutics 2.87Moderate Buy$34.2558.13% UpsideTLXTelix Pharmaceuticals 2.78Moderate Buy$21.13120.97% UpsideVKTXViking Therapeutics 2.79Moderate Buy$93.60225.57% UpsideXNCRXencor 2.40Hold$24.5098.70% UpsideCurrent Analyst Ratings BreakdownLatest XNCR, VKTX, TLX, and DNLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026VKTXViking Therapeutics Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$89.005/27/2026VKTXViking Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$83.005/22/2026DNLIDenali Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $35.005/22/2026DNLIDenali Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$31.005/14/2026DNLIDenali Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$42.00 ➝ $40.005/11/2026DNLIDenali Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$39.005/11/2026XNCRXencor JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$13.00 ➝ $14.005/8/2026DNLIDenali Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $23.005/6/2026XNCRXencor Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/1/2026VKTXViking Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.004/30/2026VKTXViking Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$95.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNLIDenali Therapeutics$330.53M10.40N/AN/A$6.91 per share3.13TLXTelix Pharmaceuticals$803.79M4.04$0.04 per share224.13$1.23 per share7.77VKTXViking TherapeuticsN/AN/AN/AN/A$5.65 per shareN/AXNCRXencor$125.58M7.28N/AN/A$8.90 per share1.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNLIDenali Therapeutics-$512.54M-$2.88N/AN/AN/AN/A-52.20%-43.86%8/10/2026 (Estimated)TLXTelix Pharmaceuticals-$7.12MN/AN/A86.91N/AN/AN/AN/A8/20/2026 (Estimated)VKTXViking Therapeutics-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)XNCRXencor-$91.92M-$2.29N/AN/AN/A-177.10%-28.77%-20.52%8/5/2026 (Estimated)Latest XNCR, VKTX, TLX, and DNLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026DNLIDenali Therapeutics-$0.73-$0.69+$0.04-$0.69$2.57 millionN/A5/6/2026Q1 2026XNCRXencor-$0.7468-$1.71-$0.9632-$1.71$27.86 million$4.52 million4/30/2026Q1 2026VKTXViking Therapeutics-$1.01-$1.37-$0.36-$1.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDNLIDenali TherapeuticsN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNLIDenali Therapeutics0.019.289.28TLXTelix Pharmaceuticals1.081.431.27VKTXViking TherapeuticsN/A5.725.72XNCRXencorN/A6.576.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNLIDenali Therapeutics92.92%TLXTelix PharmaceuticalsN/AVKTXViking Therapeutics76.03%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipDNLIDenali Therapeutics12.50%TLXTelix PharmaceuticalsN/AVKTXViking Therapeutics5.30%XNCRXencor5.08%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNLIDenali Therapeutics430158.71 million138.87 millionOptionableTLXTelix Pharmaceuticals1,184339.38 millionN/AN/AVKTXViking Therapeutics20116.11 million109.95 millionOptionableXNCRXencor28074.14 million70.38 millionOptionableXNCR, VKTX, TLX, and DNLI HeadlinesRecent News About These CompaniesIncyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trialMay 30, 2026 | seekingalpha.comJefferies Financial Group Inc. Purchases 620,440 Shares of Xencor, Inc. $XNCRMay 25, 2026 | marketbeat.comXencor IncMay 18, 2026 | money.usnews.comXencor, Inc. $XNCR Shares Sold by UBS Group AGMay 17, 2026 | marketbeat.comXencor (XNCR) Receives a Buy from Wells FargoMay 15, 2026 | theglobeandmail.comXencor, Inc. Common Stock (XNCR)May 13, 2026 | nasdaq.comXencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comThese Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under ThreatMay 8, 2026 | finance.yahoo.comXencor: Q1 Earnings SnapshotMay 6, 2026 | ctpost.comCXencor (XNCR) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | zacks.comXencor Reports First Quarter 2026 Financial ResultsMay 6, 2026 | businesswire.comXencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 TranscriptMay 5, 2026 | seekingalpha.comXencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 - SlideshowMay 5, 2026 | seekingalpha.comXencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDWMay 4, 2026 | businesswire.comJP Morgan Downgrades Xencor (XNCR)March 25, 2026 | msn.comXencor (XNCR) Receives a Buy from WedbushMarch 17, 2026 | theglobeandmail.comXencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptMarch 11, 2026 | seekingalpha.comXencor (NASDAQ:XNCR) SVP Sells $19,472.34 in StockMarch 10, 2026 | insidertrades.comXencor, Genentech to End Protein Therapeutics CollaborationMarch 9, 2026 | tipranks.comXencor (NASDAQ:XNCR) SVP Sells $17,754.80 in StockMarch 5, 2026 | insidertrades.comRoyalty Rift: Alexion Cuts Off US Royalty Payments To XencorMarch 5, 2026 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXNCR, VKTX, TLX, and DNLI Company DescriptionsDenali Therapeutics NASDAQ:DNLI$21.66 +0.64 (+3.04%) Closing price 04:00 PM EasternExtended Trading$21.66 0.00 (0.00%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Telix Pharmaceuticals NASDAQ:TLX$9.56 +0.11 (+1.16%) Closing price 04:00 PM EasternExtended Trading$9.56 -0.01 (-0.05%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.Viking Therapeutics NASDAQ:VKTX$28.75 +0.14 (+0.49%) Closing price 04:00 PM EasternExtended Trading$28.88 +0.13 (+0.44%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.Xencor NASDAQ:XNCR$12.33 +0.24 (+1.99%) Closing price 04:00 PM EasternExtended Trading$12.50 +0.17 (+1.39%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
